University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Depression
FollowWhat is new in Depression research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- AzetukalnerPhase 3 · NCT06775379 · NCT07076407 · NCT07217860 · NCT06922110
- BrenipatidePhase 3 · NCT07775300 · NCT07412756
- BrexpiprazolePhase 3 · NCT04569448
- BupropionPhase 3 · NCT05603104 · NCT05973786 · NCT04422652
- ClozapinePhase 3 · NCT05603104
- CYB003Phase 3 · NCT06793397 · NCT06820723 · NCT06605105
- Dehydroepiandrosterone (DHEA)Phase 3 · NCT07843927
- EscitalopramPhase 3 · NCT06828887 · NCT05603104 · NCT05973786
- Esketamine 56 mgPhase 3 · NCT07716098
- Esketamine 84 mgPhase 3 · NCT07716098
- Esketamine hydrochloridePhase 3 · NCT05603104 · NCT05973851
- Esketamine Nasal ProductPhase 3 · NCT05603104 · NCT05973851
- Inactive PlaceboPhase 3 · NCT06308653
- inhalation of %100 oxygen + intravenous midazolamPhase 3 · NCT07262008
- Inhalation of Nitrous oxide (Laughing gas) + intravenous salinePhase 3 · NCT07262008
- KetaminePhase 3 · NCT06668571 · NCT05915013 · NCT06480201 · NCT03573349 · NCT05625555 · NCT06410599 · NCT03065335 · NCT07247370 · NCT06559826 · NCT06781697 · NCT02122562
- Ketamine HydrochloridePhase 3 · NCT07569198 · NCT02543983 · NCT05603104 · NCT06402955 · NCT06480500 · NCT07088380 · NCT05973851
- LithiumPhase 3 · NCT05603104 · NCT05973786
- LumateperonePhase 3 · NCT07623135
- MidazolamPhase 3 · NCT06228391 · NCT05625555
- NBI-1065845Phase 3 · NCT06911112 · NCT06786624 · NCT06963021 · NCT06966401
- nebulized ketaminePhase 3 · NCT06752759
- nebulized midazolamPhase 3 · NCT06752759
- Oculus VR headsetPhase 3 · NCT06781697
- PsilocybinPhase 3 · NCT06506019 · NCT06731621 · NCT07703722 · NCT05947383 · NCT06072898 · NCT07216404 · NCT07211438 · NCT06442423 · NCT06303739 · NCT07895134 · NCT05711940 · NCT06132178 · NCT06378229 · NCT07226232 · NCT07499583
- Psilocybin 25 mgPhase 3 · NCT06518720 · NCT06308653 · NCT06512220 · NCT07405606
- Psilocybin 5 mgPhase 3 · NCT06308653
- QuetiapinePhase 3 · NCT04950868 · NCT05603104 · NCT07760168 · NCT05973786
- Repetitive Transcranial Magnetic StimulationPhase 3 · NCT06765824 · NCT04041479
- Second-line AntidepressantsPhase 3 · NCT05603104 · NCT05973851
- Second-line AntipsychoticsPhase 3 · NCT05603104
- Selective Serotonin Reuptake Inhibitor (SSRI)Phase 3 · NCT07703722
- Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)Phase 3 · NCT06559306
- SeltorexantPhase 3 · NCT06559306
- Senseye Diagnostic Tool (DT)Phase 3 · NCT07280065
- SertralinePhase 3 · NCT05603104 · NCT05973786 · NCT07645157
- Solriamfetol 150 MGPhase 3 · NCT07484217
- Transcranial Magnetic StimulationPhase 3 · NCT07745569 · NCT06719427 · NCT07760168 · NCT06376734
- Transcranial Magnetic Stimulation ShamPhase 3 · NCT06667180 · NCT06765824 · NCT07560878
- Valproate acidPhase 3 · NCT05603104 · NCT05973786
- VenlafaxinePhase 3 · NCT05603104 · NCT05973786
- Allopurinol 300 MGPhase 2/3 · NCT07574060
- Fecal Microbiota TransplantationPhase 2/3 · NCT05174273
- Ketamine (0.5 mg/kg)Phase 2/3 · NCT07801703
- Neuronavigated robotic-enabled TMSPhase 2/3 · NCT07227103
- NRX-101Phase 2/3 · NCT07785102 · NCT07227103
- Oral PlaceboPhase 2/3 · NCT07227103
- RUL LAP-ST (Low-Amplitude Pulse Seizure Therapy - Right Unilateral)Phase 2/3 · NCT06529029
- Sertraline 50 MGPhase 2/3 · NCT07574060
- Sigma-StimPhase 2/3 · NCT06529029
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)Phase 2 · NCT06511908
- 11C-UCB-JPhase 2 · NCT06402955
- Accelerated intermittent theta burst (aiTBS) rTMS treatmentPhase 2 · NCT06132178
- Accelerated rTMSPhase 2 · NCT07287839
- Active Comparator: Psilocybin with Support OnlyPhase 2 · NCT07104916
- Adalimumab Biosimilars InjectionPhase 2 · NCT07845604
- ALTO-207Phase 2 · NCT07553637
- ALTO-300Phase 2 · NCT05922878
- Apimostinel Infusion, IntravenousPhase 2 · NCT06400121
- Aripiprazole AugmentationPhase 2 · NCT07810738
- BaricitinibPhase 2 · NCT07003997
- Biospecimen CollectionPhase 2 · NCT07216404
- BMS-986511Phase 2 · NCT07772531
- BPL-003Phase 2 · NCT05660642
- Bright light therapyPhase 2 · NCT07002554
- Bupropion AugmentationPhase 2 · NCT07810738
- D-CycloserinePhase 2 · NCT05591677 · NCT07593222
- DasatinibPhase 2 · NCT05838560
- DEX IR tabletsPhase 2 · NCT06967857
- DEX XLPhase 2 · NCT06967857
- dim red lightPhase 2 · NCT07002554
- DT-101Phase 2 · NCT07300969 · NCT07610473
- Experimental Anxiety DevicesPhase 2 · NCT02543983
- High Dose 5-hydroxytryptophanPhase 2 · NCT05895747
- High Dose Creatine MonohydratePhase 2 · NCT05895747
- InfliximabPhase 2 · NCT06136546
- Intermittent Theta Burst StimulationPhase 2 · NCT05591677
- Isotonic Solution, IntravenousPhase 2 · NCT06400121
- IV ketaminePhase 2 · NCT06228391
- Ketamine hydrochloride injectionPhase 2 · NCT07247006
- L-leucinePhase 2 · NCT06580145
- L-lysinePhase 2 · NCT06580145
- LB-102Phase 2 · NCT07494305
- Low Dose 5-hydroxytryptophanPhase 2 · NCT05895747
- Low Dose Creatine MonohydratePhase 2 · NCT05895747
- Low-dose psilocybinPhase 2 · NCT06132178
- LV232 40mgPhase 2 · NCT06828887
- LV232 60mgPhase 2 · NCT06828887
- Magnetic Resonance Imaging scanner, 3TPhase 2 · NCT02543983
- Magnetic Resonance Imaging scanner, 7TPhase 2 · NCT02543983
- Medi-TBSPhase 2 · NCT07512284 · NCT06399406
- Midazolam HydrochloridePhase 2 · NCT07569198 · NCT06480500
- modafinilPhase 2 · NCT07895134
- N,N-Dimethyltryptamine (1 mg + 4 mg)Phase 2 · NCT07562191
- N,N-Dimethyltryptamine (15 mg + 60 mg)Phase 2 · NCT07562191
- NeurOptics PLRTM-3000 PupillometerPhase 2 · NCT02543983
- Normal SalinePhase 2 · NCT06668571
- Normal Saline (0.9% NaCl)Phase 2 · NCT07052058
- Omega 3Phase 2 · NCT05774665
- OSU6162Phase 2 · NCT05296356
- Parcel-guided Accelerated rTMSPhase 2 · NCT07287839
- pimavanserinPhase 2 · NCT07895134
- Pramipexole Immediate ReleasePhase 2 · NCT07022405
- PregnenolonePhase 2 · NCT07685964 · NCT05570812
- PropofolPhase 2 · NCT07479550
- psilocybin (25 mg)Phase 2 · NCT06943573
- Psilocybin (drug)Phase 2 · NCT07745569 · NCT07183748 · NCT07566104
- Psilocybin (Usona Institute)Phase 2 · NCT07251491 · NCT07479550 · NCT07490353
- Psilocybin + MBCT therapyPhase 2 · NCT07104916
- psilocybin 1 mg sodPhase 2 · NCT06319378
- psilocybin 1mg micro-dosePhase 2 · NCT06943573
- Psilocybin 25 mg per osPhase 2 · NCT07210112
- psilocybin 25 mg sodPhase 2 · NCT06319378
- Psilocybin 25mgPhase 2 · NCT07373535
- Psilocybin therapyPhase 2 · NCT06782724
- quercetinPhase 2 · NCT05838560
- Risperidone 1 MGPhase 2 · NCT06512220 · NCT07490353
- selenium yeast supplementationPhase 2 · NCT07203144
- Sertraline combined with Lactobacillus crispatusPhase 2 · NCT07539805
- Sertraline combined with placeboPhase 2 · NCT07539805
- Single Psychedelic Dose PsilocybinPhase 2 · NCT06341426
- Sodium lactatePhase 2 · NCT06168175
- SPT-300Phase 2 · NCT07065240 · NCT07161700
- thiamine hydrochloride 100 mgPhase 2 · NCT07793071
- TNX-102 SLPhase 2 · NCT07621237
- TocilizumabPhase 2 · NCT07052058 · NCT07493317
- Trazodone 30 mgPhase 2 · NCT07210112
- Trazodone 5mgPhase 2 · NCT07210112
- Treatment with Ketamine Hydrochloride Prolonged-Release TabletsPhase 2 · NCT07396272
- Two Psychedelic Doses PsilocybinPhase 2 · NCT06341426
- zolpidemPhase 2 · NCT07895134
- DextromethophanPhase 1/2 · NCT07593222
- ELE-101Phase 1/2 · NCT05434156
- ELE-101 PlaceboPhase 1/2 · NCT05434156
- EnoxolonePhase 1/2 · NCT05570110
- FluoxetinePhase 1/2 · NCT06898606
- Full-spectrum CBD oil 100 mg/mLPhase 1/2 · NCT07696871
- High-intensity (6 mA) transcranial direct current stimulation (tDCS)Phase 1/2 · NCT07657234
- Low-intensity TMSPhase 1/2 · NCT06667180
- Nicotine Replacement TherapyPhase 1/2 · NCT00494728
- PDC-1421 CapsulePhase 1/2 · NCT03833206
- Psilocybin and PsilocynPhase 1/2 · NCT06898606
- TMSPhase 1/2 · NCT07593222 · NCT07785102
- transcutaneous spinal direct current stimulationPhase 1/2 · NCT06795451
- Transdermal patch estradiolPhase 1/2 · NCT04685148
- Transdermal patch placeboPhase 1/2 · NCT04685148
- 0.1 mg/kg Dimethyltryptamine (DMT)Phase 1 · NCT04711915
- 0.3 mg/kg Dimethyltryptamine (DMT)Phase 1 · NCT04711915
- 11C-MCIPhase 1 · NCT04582916
- 11CPS13Phase 1 · NCT04582916
- 18F-PF-06445974Phase 1 · NCT05703685
- 75 mg of oral ketaminePhase 1 · NCT07683988
- ApremilastPhase 1 · NCT05703685
- Arm 1 and 2 InterventionsPhase 1 · NCT03973268
- Arm 1, 2, 3 device interventionsPhase 1 · NCT03973268
- Arm 1, 2, 3 drug InterventionsPhase 1 · NCT03973268
- Cobot TS MV robotic arm for TMSPhase 1 · NCT03065335
- Compressed iTBSPhase 1 · NCT07033780
- DMT-Low DosePhase 1 · NCT06671977
- DMT-Medium DosePhase 1 · NCT06671977
- Extended-Release MemantinePhase 1 · NCT07139834
- Functional MRIPhase 1 · NCT06506019
- LSDPhase 1 · NCT07503002
- Lung scanPhase 1 · NCT05703685
- Medtronic SenSight Directional DBS leadPhase 1 · NCT06096207
- NeurOptics PLRTM-30000 PupillometerPhase 1 · NCT03065335
- Nitrous OxidePhase 1 · NCT03736538
- PerampanelPhase 1 · NCT05915013
- Repetitive Transcranial Magnetic Stimulation (rTMS)Phase 1 · NCT07562074
- RisperidonePhase 1 · NCT07503002
- Spaced iTBSPhase 1 · NCT07033780
- SSRI (escitalopram or sertraline)Phase 1 · NCT07139834
- Sublingual ketamine 75 mgPhase 1 · NCT07683988
- THC-Low DosePhase 1 · NCT06671977
- THC-Medium DosePhase 1 · NCT06671977
- Active Repetitive Transcranial Magnetic Stimulation (rTMS)Early phase 1 · NCT07804459
- BaclofenEarly phase 1 · NCT07560878
- Continuous theta-burst stimulation (cTBS)Early phase 1 · NCT07560878
- D-Cycloserine (DCS)Early phase 1 · NCT07560878
- Deep Brain Stimulation(DBS)Early phase 1 · NCT06784388
- EsketamineEarly phase 1 · NCT06784388
- Lorazepam (drug)Early phase 1 · NCT07560878
- MemantineEarly phase 1 · NCT07560878
Closest to patients
- Neurocognitive Effects of FMT in MDD Patients With and Without IBSNeurocognitive Effects of FMT in MDD Patients With and Without IBSUniversity of Calgary, TRW building · Calgary, CanadaPhase 2/3Primary completion 2024
- Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDEfficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDAdams Clinical - Boston (Copley Clinical) · Boston, United States + 115 more hospitalsPhase 3Primary completion 2025
- Psilocybin for Major Depressive Disorder (MDD)Psilocybin for Major Depressive Disorder (MDD)Cedar Clinical Research, Inc. · Murray, United States + 28 more hospitalsPhase 3Results expected 2026
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Polygenic prediction of cannabis-related outcomes: Evidence from the Avon Longitudinal Study of Parents and Children longitudinal cohort and the European gene-environment interaction case-control study.
Polygenic prediction of cannabis-related outcomes: Evidence from the Avon Longitudinal Study of Parents and Children longitudinal cohort and the European gene-environment interaction case-control study.
Addiction (Abingdon, England)
PubMed · PMID 42929306Publication
The Association Between Vitamin D Status and Depression Severity in Adults with Major Depressive Disorder: A Cross-Sectional Study.
The Association Between Vitamin D Status and Depression Severity in Adults with Major Depressive Disorder: A Cross-Sectional Study.
International journal of molecular sciences
PubMed · PMID 42794622Publication
Comparing the Impact of Tetrahydrocannabinol on 30-Day Readmission Rates and Hospital Length of Stay in Patients With Depression.
Comparing the Impact of Tetrahydrocannabinol on 30-Day Readmission Rates and Hospital Length of Stay in Patients With Depression.
Brain and behavior
PubMed · PMID 42779162
Find fellow researchers
Groups with active Depression work.
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
King's College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Massachusetts General Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Yale University
New Haven, United States
Team details appear once the team leader joins.
Is this your team? Claim it
The University of Melbourne
Melbourne, Australia
Team details appear once the team leader joins.
Is this your team? Claim it
Stanford University
Stanford, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Peking University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Zhejiang University
Hangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Nanjing Medical University
Nanjing, China
Team details appear once the team leader joins.
Is this your team? Claim it